within the promptly evolving industry of oncology study, precise and effective mutation screening is crucial for establishing focused therapies. The KRAS products and services System performs a pivotal purpose in this landscape by presenting complete solutions for KRAS mutation profiling and analysis. KRAS mutations, found in about ninety five% of